MedTrace Logo

The Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis

NCT02009293 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2016-12-23

No results posted yet for this study

Summary

In this study we evaluate the effect of Pirfenidone on cough and quality of life in patients with idiopathic pulmonary fibrosis (IPF) that are treated with Pirfenidone in daily practice. The hypothesis is that Pirfenidone will decrease cough and increase quality of life.

Conditions

Interventions

OTHER

Cough monitor

questionnaires about cough and quality of life

Sponsors & Collaborators

  • University of Catania

    collaborator OTHER

  • University of Lyon

    collaborator OTHER

  • King's College Hospital NHS Trust

    collaborator OTHER

  • Royal Brompton & Harefield NHS Foundation Trust

    collaborator OTHER

  • Erasmus Medical Center

    lead OTHER

Principal Investigators

  • M. S. Wijsenbeek, Dr. · Erasmus Medical Centre Rotterdam, The Netherlands

  • C. Vancheri, Prof. · University of Catania, Italy

  • V. Cottin, Prof. · Louis Pradel hospital, Lyon, France

  • S Birring, Dr. · Department of Respiratory Medicine,King's College Hospital.Denmark Hill, London

  • A Russell · Royal Brompton & Harefield NHS Foundation Trust

  • E Renzoni, Dr. · Royal Brompton & Harefield NHS Foundation Trust

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • France
  • Italy
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02009293 on ClinicalTrials.gov